177Lu-DOTA-EB-TATE in Untreated (Naïve) Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
Status:
Recruiting
Trial end date:
2024-03-30
Target enrollment:
Participant gender:
Summary
This is a Phase I clinical trial to assess the safety and dosimetry profiles of
177Lu-DOTA-EB-TATE in patients with advanced, metastatic or inoperable, somatostatin
receptor-positive, well-differentiated GEP-NETs.